SAB Biotherapeutics Progressing on Therapeutic for COVID-19

Click Here To View


A natural match for the complexity of human disease.

Modern medicine struggles to keep pace with the emergence, mutation, and diversity of disease. The body’s natural defense system produces polyclonal antibodies against invaders such as viruses, allergens, bacteria, toxins, and other pathogens.

SAB Biotherapeutics has developed a first-of-its-kind therapeutic engine—unleashing the power of the body’s native biological defense system to produce immunotherapies that have the potential to truly match and overpower the complexity, diversity, and evolution of human disease.

This new class of immunotherapies opens the door to novel medicines that are potentially safer, more effective, and longer lasting than current antibody therapies.

About featured image

The sophistication of science. The genius of nature.

Through remarkable genetic engineering, we've developed the DiversitAb™ platform to harness the native human antibody immune response. Our novel therapeutic engine can produce medicines—human polyclonal antibodies—for a broad array of pathogens to treat modern health challenges such as seasonal influenza, Type 1 diabetes, and cancers.

  • Microscope image

    Advanced engineering and a refined suite of technologies optimized over nearly two decades

  • Engine image

    Broad therapeutic reach in autoimmunity, infectious disease, inflammation and oncology

Immunotherapies will never be the same.

No other immunotherapies so fully capture the power of the human humoral immune response with natural synergistic targeting to the complexity of disease. Our therapeutic engine is capable of rapidly generating fully human polyclonal antibodies at commercial scale, armed against targeted pathogens.

  • Immunity image

    Natural, custom, high-potency immunotherapies with superior safety profile

  • Vial image

    Longer-lasting, broad spectrum activity compared to current antibody therapies

Lab image

Robust Pipeline with Broad Therapeutic Reach

Ready for rapid response. Because we can.

The speed and sophistication of our platform means we can address global health threats in ways only we can. We’re ready to respond quickly to epidemic-level pathogens, and we’re already developing treatments for some of the world’s most imminent health threats.

  • Media left icon

    Awarded $27 million competitive contract from the U.S. Department of Defense to develop and test an accelerated and effective rapid response capability, at scale

  • Media right icon

    Recognized as the only therapeutic platform to address priority pathogens by the World Health Organization

Contact Us

2100 East 54th Street North
Sioux Falls, SD 57104

245 First Street, Suite 1836
Cambridge, MA 02142